Both Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Intec Pharma Ltd. (NASDAQ:NTEC) are each other’s competitor in the Biotechnology industry. Thus the contrast of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.
Table 1 highlights Jazz Pharmaceuticals plc and Intec Pharma Ltd.’s gross revenue, earnings per share and valuation.
Table 2 shows the return on equity, net margins and return on assets of the two firms.
The Recommendations and Ratings for Jazz Pharmaceuticals plc and Intec Pharma Ltd. are featured in the next table.
$185 is Jazz Pharmaceuticals plc’s consensus target price while its potential upside is 47.65%.
Institutional and Insider Ownership
Roughly 95.9% of Jazz Pharmaceuticals plc shares are owned by institutional investors while 40.62% of Intec Pharma Ltd. are owned by institutional investors. Jazz Pharmaceuticals plc’s share owned by